Targeting HER2-positive breast cancer: advances and future …
Nov 7, 2022 · Innovations in pathology, molecular biology and drug development have enabled HER2-positive breast cancer (BC), a historically aggressive subtype, to become one with impressive outcomes.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
May 3, 2024 · On August 5, the agency gave an accelerated approval for trastuzumab deruxtecan —often called T-DXd—to treat anyone with any advanced solid cancer if their tumors produce high levels of the protein HER2, or HER2-positive.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
Oct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
Greater Precision of HER2-Expressing Breast Cancer Treatment …
1 day ago · In HER2-low and HER2-ultralow metastatic breast cancer, the novel antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has demonstrated robust efficacy over conventional chemotherapy.
HER2-positive breast cancer treatments - Mayo Clinic Press
Jul 24, 2024 · Traditional chemotherapy, radiation and surgery still play an important role in the treatment of HER2-positive cancers. These treatments often are used along with newer treatments that target HER2-positive cancer in slightly different ways. There are three main types of HER2-targeted therapies.
Emerging treatments in HER2-positive advanced breast cancer: …
Jun 18, 2024 · This review describes the evolving treatment landscape of HER2-positive breast cancer, from the current approved therapies to the future perspectives, with a focus on the new agents that are likely to get regulatory approval in the near future.
FDA Approves New Drug Combination for ER+, HER2- Breast …
Oct 10, 2024 · The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets …
FDA Approves New ADC for HR+, HER2- Breast Cancer - Medscape
Jan 17, 2025 · The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human...
Greater Precision of HER2-Expressing Breast Cancer Treatment …
2 days ago · The study found that JelloX's 3D pathology technology identified a significantly increased proportion of tumors with HER2-low and HER2-ultralow expression compared to conventional methods ...
Thousands of people a year could benefit from new twice-a-day …
Apr 11, 2025 · 1000s of people could benefit from new twice-a-day tablet for advanced breast cancer recommended by NICE.